Halsey's Endometriosis Journey: The Private-Clinic Pathway They Likely Used

What Halsey Actually Said About Endometriosis

Halsey has spoken openly about endometriosis for years, describing painful periods and a body that felt chronically under siege. In 2022 they announced a cluster of diagnoses including endometriosis, lupus, Sjögren syndrome, mast cell activation syndrome, and a T-cell lymphoma. The endometriosis disclosure, though, had been building for over a decade of public statements about debilitating menstrual pain.

That pattern of delayed, multi-diagnosis revelation is not unique to Halsey. It is the statistical norm.

Diagnostic delay averages 7 to 10 years from first symptom to confirmed endometriosis diagnosis. Women are regularly told their pain is psychological, normal, or manageable with ibuprofen. Halsey used their platform to say, plainly, that this is not acceptable. That advocacy matters clinically because earlier diagnosis translates to less disease progression and better fertility preservation.

Why the Diagnostic Delay Is So Long for Women

The delay is not accidental. It is structural. Endometriosis pain is dismissed partly because menstrual pain is culturally normalized, and partly because the only definitive diagnostic tool is surgery. A 2017 study in the American Journal of Obstetrics and Gynecology found that women saw an average of 4.2 physicians before receiving a diagnosis. Many of those visits resulted in reassurance rather than referral.

Private-clinic pathways exist specifically to compress this timeline. A woman who pays for specialist access skips the general-practitioner referral queue and lands directly in front of a gynecologist or reproductive endocrinologist who treats endometriosis as a primary subspecialty.

The Public Advocacy Effect

When a public figure names their endometriosis diagnosis, search traffic for "endometriosis symptoms" spikes within days. This is not trivial. Research published in Fertility and Sterility suggests that patient education and awareness are among the most effective tools for shortening diagnostic delay. Halsey's disclosures fit that pattern.

What the Private-Clinic Endometriosis Pathway Actually Looks Like

The private-clinic pathway is a compressed, specialist-directed diagnostic and treatment sequence. It is not magic. It is the same evidence-based medicine available on the NHS or through US insurance, delivered faster and with more continuity of care. Here is what each stage involves.

Stage 1: Specialist Consultation and Symptom Mapping

A private endometriosis clinic does not start with imaging. It starts with a detailed symptom history, usually conducted by a gynecologist or reproductive endocrinologist who subspecializes in endometriosis. Questions cover:

• Cycle length, flow volume, and pain severity using a validated scale such as the numerical rating scale or the Biberoglu and Behrman scale
• Pain location (central pelvic, unilateral, radiating to the rectum or legs)
• Cyclical bowel or bladder symptoms, which may indicate deep infiltrating endometriosis
• Fertility goals, because treatment sequencing differs substantially depending on whether a woman is trying to conceive

The ESHRE endometriosis guideline (2022) recommends that clinicians take a full medical and surgical history before any investigation. Private clinics tend to allocate 45 to 90 minutes for this first appointment. NHS first appointments are often 15 minutes.

Stage 2: Imaging (and Its Limitations)

Transvaginal ultrasound (TVUS) is the first imaging modality in most private pathways. Performed by a sonographer trained specifically in endometriosis mapping, TVUS can detect endometriomas (ovarian cysts caused by endometriosis) and deep infiltrating disease with reasonable accuracy.

A systematic review in Ultrasound in Obstetrics and Gynecology found that TVUS has a sensitivity of 93% and specificity of 96% for ovarian endometriomas, but is substantially less reliable for superficial peritoneal disease. This matters because superficial disease is common, painful, and easily missed on imaging.

MRI of the pelvis adds information about deep infiltrating lesions, particularly those involving the bowel, bladder, or uterosacral ligaments. Private clinics often order both modalities before offering a surgical opinion.

The ceiling of all imaging: a normal scan does not rule out endometriosis.

Stage 3: Hormonal Trial or Surgical Referral

After imaging, the pathway branches.

Branch A: Hormonal suppression trial. For women not planning immediate conception, a trial of hormonal treatment is both diagnostic and therapeutic. The ACOG Practice Bulletin on Endometriosis supports empiric hormonal treatment in women with classic symptoms and no immediate surgical indication. Options include:

• Combined oral contraceptive pills (continuous or cyclic)
• Progestin-only pills or the 52 mg levonorgestrel IUD
• GnRH agonists (leuprolide, nafarelin) or the newer GnRH antagonists (elagolix, relugolix)

If pain improves on hormonal suppression, the clinical diagnosis of endometriosis is strengthened without surgery. If it does not improve, surgical evaluation is the next step.

Branch B: Laparoscopy for diagnosis and treatment. Laparoscopy with direct visualization and biopsy remains the gold standard for definitive diagnosis. The procedure allows the surgeon to grade disease, biopsy lesions for histological confirmation, and treat visible disease in the same operation.

Stage 4: Excision, Not Ablation

This is where private specialist care diverges most sharply from general gynecology.

Ablation (also called fulguration or coagulation) destroys endometriosis lesions on the surface using heat or laser. It is fast and familiar to most gynecologists. Excision cuts lesions out completely, including their root. It requires more surgical skill and longer operating time.

A randomized controlled trial published in the BMJ found that excision of endometriosis at laparoscopy was significantly more effective than diagnostic laparoscopy alone for reducing pain at 6 months. Long-term follow-up data consistently shows lower recurrence rates with excision compared to ablation, particularly for deep infiltrating disease.

Private endometriosis specialists, including those at centres in London, New York, and Melbourne that cater to high-profile patients, are almost universally trained excision surgeons. The ability to access an excision-trained surgeon is probably the single largest clinical advantage of the private pathway.

Endometriosis Across Life Stages: What Changes

Endometriosis is not one static disease. Its clinical picture shifts substantially depending on where a woman is in her reproductive life, and the treatment approach must shift accordingly. Most published guidelines and most public conversations treat endometriosis as a disease of the mid-reproductive years. The reality is more complicated.

Adolescence and First Symptoms (Ages 12-21)

Endometriosis can begin at the first menstrual period. A study in the Journal of Pediatric and Adolescent Gynecology found that among adolescents with chronic pelvic pain who underwent laparoscopy, 49 to 65% had endometriosis confirmed histologically. Yet teenagers are the demographic most likely to be told their pain is "just period cramps."

First-line treatment in adolescents is usually a combined oral contraceptive pill or a progestin. GnRH agonists are used cautiously in this group because bone density accrual is still occurring before age 25, and GnRH agonists reduce estrogen and therefore slow bone mineralization.

Reproductive Years and Fertility Planning (Ages 22-40)

This is the stage where Halsey's public narrative sits. The reproductive-years presentation involves cyclical pelvic pain, dysmenorrhea, dyspareunia (pain during sex), and, in a substantial subset, subfertility.

Endometriosis is found in 25-50% of women investigated for infertility, according to data from the ASRM. The mechanism is multifactorial: inflammation alters the peritoneal environment, ovarian endometriomas can damage follicle reserves, and adhesions can obstruct the fallopian tubes.

For women trying to conceive, hormonal suppression is paused. Surgical treatment of endometriomas and adhesions may improve natural conception rates. IVF is often the next step if surgery alone is insufficient.

Perimenopause (Ages 40-52, approximately)

Endometriosis does not retire at perimenopause. Fluctuating estrogen levels during the menopause transition can actually exacerbate symptoms in some women. The hormonal volatility of perimenopause feeds estrogen-dependent endometriosis tissue unpredictably.

Women in perimenopause with endometriosis face a particular treatment dilemma: menopausal hormone therapy (MHT), which many perimenopausal women need for vasomotor symptoms and bone protection, contains estrogen that could theoretically stimulate residual endometriosis. The British Menopause Society advises that MHT can be used after surgical menopause for endometriosis, preferably with a progestogen component and after thorough discussion of individual risk.

After Menopause

Endometriosis is estrogen-dependent but not exclusively so. Postmenopausal endometriosis does occur, and rare cases of malignant transformation of endometriomas into clear-cell or endometrioid ovarian carcinoma have been documented. A meta-analysis in the American Journal of Obstetrics and Gynecology estimated that women with endometriosis have approximately a 1.3-fold increased relative risk of ovarian cancer, though the absolute risk remains low. Postmenopausal women with a history of endometriosis should maintain their gynecologic surveillance.

The Hormonal Treatments: What They Are, How They Work, and What Changes for Women

Combined Oral Contraceptives

COCs suppress ovulation and create a more stable, lower-estrogen environment that reduces endometriosis-driven inflammation. Continuous use (no pill-free interval) is often more effective than cyclic use for pain control. They are first-line for most reproductive-age women who do not want to conceive.

Side effects relevant to women: mood changes, libido reduction, and a small increase in VTE risk, particularly in smokers and women over 35.

Progestins

Progestins work by causing endometrial atrophy and reducing lesion activity. Options include norethindrone acetate 5 mg daily, medroxyprogesterone acetate, and the 52 mg levonorgestrel IUD. The IUD delivers progestin locally, which limits systemic side effects while still suppressing lesions within the pelvis.

A Cochrane review found that the levonorgestrel IUD reduces endometriosis-associated pain comparably to GnRH agonist therapy with a more favorable side-effect profile.

GnRH Agonists and Antagonists

GnRH agonists (leuprolide acetate 3.75 mg monthly IM, or 11.25 mg every 3 months) work by initially stimulating then suppressing gonadotropin release, creating a temporary medical menopause. This is highly effective for pain but produces significant menopausal side effects: hot flushes, bone density loss, vaginal dryness, and mood disturbance.

Add-back therapy (low-dose estrogen plus progestogen) is typically co-prescribed to protect bone density when GnRH agonists are used beyond 6 months. The FDA-approved labeling for leuprolide limits monotherapy to 6 months without add-back for this reason.

GnRH antagonists (elagolix 150 mg daily or 200 mg twice daily) work faster, with no initial flare, and the dose can be titrated to produce partial rather than full estrogen suppression, reducing the bone-density side effect. The ELARIS EM-I and EM-II trials demonstrated that elagolix significantly reduced dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 and 6 months.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section is required, not optional, and the stakes are high.

Pregnancy Safety

Most hormonal endometriosis treatments are contraindicated in pregnancy.

• Combined oral contraceptives: Contraindicated in confirmed pregnancy. Inadvertent first-trimester exposure is not associated with major fetal malformation based on epidemiological data, but COCs must be stopped immediately on confirmed pregnancy.
• GnRH agonists (leuprolide): Pregnancy category X. The FDA label states that leuprolide may cause fetal harm and is absolutely contraindicated in pregnancy. Women must use non-hormonal contraception during treatment or confirm they are not at risk of conception.
• Elagolix (Orilissa): Also pregnancy category X. AbbVie's prescribing information requires a negative pregnancy test before initiation and advises use of effective non-hormonal contraception during treatment and for one week after stopping the 200 mg twice-daily dose.
• Norethindrone acetate 5 mg: Contraindicated in pregnancy. High-dose progestins have been associated with virilization of female fetuses in older literature, though this risk is lower with norethindrone than with older progestins.
• Danazol: Absolutely contraindicated in pregnancy due to risk of female fetal virilization. Danazol is rarely used as first-line therapy today but is still occasionally prescribed.

Lactation

Hormonal endometriosis treatments vary in their lactation safety:

• Progestin-only options (norethindrone, levonorgestrel IUD): Generally considered compatible with breastfeeding. The levonorgestrel IUD is a common postpartum choice because systemic absorption is minimal.
• Combined oral contraceptives: Best avoided in the first 6 weeks postpartum due to effects on milk supply and neonatal VTE risk from transferred estrogen.
• GnRH agonists and antagonists: Not recommended during lactation. Data are limited and these agents suppress estrogen, which may impair milk production and have unknown effects on the infant.

Contraception Requirements

Women on GnRH antagonists or agonists are often told these drugs provide contraception. This is not accurate. GnRH agonists cause an initial hormonal flare that can allow ovulation before suppression is established. GnRH antagonists at lower doses may not fully suppress ovulation. The ASRM recommends that barrier contraception be used during GnRH agonist treatment unless the woman has a documented surgical cause of infertility.

Who This Pathway Is Right For (and Who It Is Not)

Right for You If:

• You have had pelvic pain for more than 6 months that has not responded to standard analgesics
• You have been told your ultrasound is "normal" but your symptoms persist
• You are planning a pregnancy in the next 1-3 years and want to understand your baseline fertility
• You have a known endometrioma that is growing
• You are in perimenopause with worsening pelvic pain and a history of suspected endometriosis

Not the Right Starting Point If:

• Your pain is clearly related to another cause (confirmed fibroids, ovarian torsion, acute infection)
• You are currently pregnant
• You have a bleeding disorder that increases surgical risk substantially
• Your primary goal is hormonal contraception, not endometriosis management, and your symptoms are mild

The Evidence Gap: What We Know and What We Are Guessing

Women have been systematically underrepresented in pain research and in endometriosis trials specifically. Several important evidence gaps remain:

1. Most GnRH antagonist trials ran for 6 months. Long-term data beyond 2 years in large populations do not yet exist.
2. Excision vs. Ablation has been studied in relatively small trials. The BMJ trial cited above included 174 women. That is not a large sample for a disease affecting an estimated 176 million women worldwide.
3. Racial and ethnic disparities in endometriosis diagnosis are real and underresearched. A study in the American Journal of Obstetrics and Gynecology found that Black women were significantly less likely to receive a laparoscopic endometriosis diagnosis despite similar symptom burden, suggesting differential access to the specialist evaluation this article describes.
4. The effect of endometriosis treatment on long-term sexual function, mental health, and quality of life is measured inconsistently across trials, meaning aggregate conclusions are unreliable.

When your clinician recommends a specific treatment, ask directly: "Is this based on data from women like me, or extrapolated from a different population?" That question is not difficult. The honest answer will tell you something useful about how your provider thinks.

What a Realistic Private-Clinic Timeline Looks Like

| Stage | Typical timeframe | Key decision point | |---|---|---| | Initial specialist consultation | Week 1-2 | Symptom mapping, imaging order | | TVUS (endometriosis-trained sonographer) | Week 2-4 | Endometrioma identified or ruled out | | Pelvic MRI if indicated | Week 3-5 | Deep infiltrating disease assessment | | Hormonal trial OR surgical referral | Week 4-8 | Fertility goals, severity, imaging results | | Laparoscopy (if surgical) | Week 8-20 | Disease staging, excision | | Post-operative hormonal maintenance | Ongoing | Recurrence prevention |

The NHS pathway for the same sequence, through standard referral, commonly takes 18 months to 3 years in the UK. US insurance timelines vary but specialty wait times of 3 to 9 months for a first endometriosis consultation are common in major cities.